Q3 2018 Earnings Forecast for Arrowhead Pharmaceuticals (ARWR) Issued By Jefferies Group

Arrowhead Pharmaceuticals (NASDAQ:ARWR) – Analysts at Jefferies Group cut their Q3 2018 earnings estimates for Arrowhead Pharmaceuticals in a note issued to investors on Wednesday, May 9th, according to Zacks Investment Research. Jefferies Group analyst M. Raycroft now expects that the biotechnology company will post earnings of ($0.20) per share for the quarter, down from their previous forecast of ($0.18). Jefferies Group currently has a “Buy” rating and a $10.00 price objective on the stock. Jefferies Group also issued estimates for Arrowhead Pharmaceuticals’ Q4 2018 earnings at ($0.20) EPS, FY2018 earnings at ($0.76) EPS and FY2021 earnings at ($0.08) EPS.

ARWR has been the topic of several other reports. Cantor Fitzgerald set a $5.00 target price on shares of Arrowhead Pharmaceuticals and gave the stock a “neutral” rating in a research report on Monday, February 12th. ValuEngine raised shares of Arrowhead Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, May 2nd. BidaskClub downgraded shares of Arrowhead Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, April 19th. Piper Jaffray Companies lifted their target price on shares of Arrowhead Pharmaceuticals to $11.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 8th. Finally, Chardan Capital reissued a “buy” rating and issued a $7.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Monday, February 19th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. Arrowhead Pharmaceuticals has an average rating of “Buy” and an average price target of $9.00.

Arrowhead Pharmaceuticals stock opened at $9.77 on Monday. The company has a market capitalization of $875.77 million, a PE ratio of -20.79 and a beta of 2.41. The company has a current ratio of 10.16, a quick ratio of 10.16 and a debt-to-equity ratio of 0.02. Arrowhead Pharmaceuticals has a fifty-two week low of $1.42 and a fifty-two week high of $10.38.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its earnings results on Tuesday, May 8th. The biotechnology company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.01. The business had revenue of $0.65 million for the quarter, compared to the consensus estimate of $4.04 million. Arrowhead Pharmaceuticals had a negative net margin of 199.55% and a negative return on equity of 50.05%.

A number of hedge funds have recently bought and sold shares of ARWR. Quantitative Systematic Strategies LLC bought a new stake in Arrowhead Pharmaceuticals in the first quarter worth approximately $100,000. Vanguard Capital Wealth Advisors bought a new stake in Arrowhead Pharmaceuticals in the fourth quarter worth approximately $119,000. Macquarie Group Ltd. bought a new stake in Arrowhead Pharmaceuticals in the fourth quarter worth approximately $123,000. Jane Street Group LLC bought a new stake in Arrowhead Pharmaceuticals in the fourth quarter worth approximately $130,000. Finally, Trexquant Investment LP bought a new stake in Arrowhead Pharmaceuticals in the first quarter worth approximately $139,000. 44.58% of the stock is owned by institutional investors.

In other Arrowhead Pharmaceuticals news, CFO Kenneth Allen Myszkowski sold 20,000 shares of the business’s stock in a transaction that occurred on Tuesday, March 27th. The shares were sold at an average price of $8.00, for a total value of $160,000.00. Following the completion of the sale, the chief financial officer now directly owns 330,815 shares of the company’s stock, valued at $2,646,520. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Christopher Richard Anzalone sold 300,000 shares of the business’s stock in a transaction that occurred on Thursday, March 15th. The stock was sold at an average price of $7.43, for a total transaction of $2,229,000.00. Following the completion of the sale, the chief executive officer now directly owns 2,194,789 shares of the company’s stock, valued at $16,307,282.27. The disclosure for this sale can be found here. Insiders have sold 465,000 shares of company stock worth $3,432,350 over the last ninety days. 4.60% of the stock is currently owned by insiders.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. Its pre-clinical stage medicines include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; ARO-APOC3 and ARO-ANG3 to treat hypertriglyceridemia; ARO-Lung1 for the treatment of an undisclosed pulmonary target; ARO-HIF2 to treat renal cell carcinoma; ARO-F12 for hereditary angioedema and thromboembolic disorders; and ARO-AMG1 for the treatment of an undisclosed genetically validated cardiovascular target.

Get a free copy of the Zacks research report on Arrowhead Pharmaceuticals (ARWR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply